The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker

[1]  Charles Swanton,et al.  Genetic prognostic and predictive markers in colorectal cancer , 2011, Nature Reviews Cancer.

[2]  M. Bertagnolli,et al.  Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis. , 2010, Cancer research.

[3]  B. Smedsrød,et al.  Colon carcinoma cell interaction with liver sinusoidal endothelium inhibits organ‐specific antitumor immunity through interleukin‐1‐induced mannose receptor in mice , 2010, Hepatology.

[4]  M. Abreu,et al.  Regulation of Toll-like receptor 4-associated MD-2 in intestinal epithelial cells: a comprehensive analysis , 2010, Innate immunity.

[5]  R. DuBois,et al.  The role of COX-2 in intestinal inflammation and colorectal cancer , 2010, Oncogene.

[6]  Z. Qian,et al.  High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer , 2010, British Journal of Cancer.

[7]  A. Iwasaki,et al.  Regulation of Adaptive Immunity by the Innate Immune System , 2010, Science.

[8]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[9]  V. Torri,et al.  CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. , 2009, The Lancet. Oncology.

[10]  K. Garber.  First results for agents targeting cancer-related inflammation. , 2009, Journal of the National Cancer Institute.

[11]  S. Lipkin,et al.  Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer. , 2009, Cancer research.

[12]  B. Evers,et al.  Toll-like receptor 4 activation increases Akt phosphorylation in colon cancer cells. , 2009, Anticancer research.

[13]  P. Allavena,et al.  Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. , 2009, Carcinogenesis.

[14]  R. Bresalier.  Early Detection of and Screening for Colorectal Neoplasia , 2009, Gut and liver.

[15]  J. Scheller,et al.  Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease. , 2009, Current pharmaceutical design.

[16]  Elizabeth L. Barry,et al.  Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. , 2009, Journal of the National Cancer Institute.

[17]  R. Gong.  Multi-target anti-inflammatory action of hepatocyte growth factor. , 2008, Current opinion in investigational drugs.

[18]  Randall Harris,et al.  Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors , 2008, BMC Cancer.

[19]  H. Brenner,et al.  Should colorectal cancer screening start at the same age in European countries? Contributions from descriptive epidemiology , 2008, British Journal of Cancer.

[20]  B. Levin,et al.  Chemoprevention of colorectal neoplasia: the potential for personalized medicine. , 2008, Gastroenterology.

[21]  D. Hackam,et al.  The role of epithelial Toll‐like receptor signaling in the pathogenesis of intestinal inflammation , 2008, Journal of leukocyte biology.

[22]  M. Karin.  The IκB kinase – a bridge between inflammation and cancer , 2008, Cell Research.

[23]  D. Noonan,et al.  Inflammation, inflammatory cells and angiogenesis: decisions and indecisions , 2008, Cancer and Metastasis Reviews.

[24]  G. Dranoff,et al.  Inciting inflammation: the RAGE about tumor promotion , 2008, The Journal of experimental medicine.

[25]  P. Nambiar,et al.  Rapid reversal of interleukin-6-dependent epithelial invasion in a mouse model of microbially induced colon carcinoma. , 2007, Carcinogenesis.

[26]  R. Xu,et al.  Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. , 2007, Gastroenterology.

[27]  L. Coussens,et al.  Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression , 2007, Breast Cancer Research.

[28]  C. Garlanda,et al.  Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family. , 2007, Cancer research.

[29]  M. Bertagnolli.  Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back. , 2007, The Lancet. Oncology.

[30]  A. Sica,et al.  Altered macrophage differentiation and immune dysfunction in tumor development. , 2007, The Journal of clinical investigation.

[31]  B. Shalmon,et al.  CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. , 2007, Cancer research.

[32]  M. Sporn,et al.  The tumour microenvironment as a target for chemoprevention , 2007, Nature Reviews Cancer.

[33]  A. Griffioen,et al.  Proliferating endothelial cells and leukocyte infiltration as prognostic markers in colorectal cancer. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[34]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[35]  L. Coussens,et al.  Analysis of immune cell infiltrates during squamous carcinoma development. , 2006, The journal of investigative dermatology. Symposium proceedings.

[36]  Yuan‐Chiang Chung,et al.  Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma. , 2006, Anticancer research.

[37]  J. Wang,et al.  Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-κB-dependent activation of the urokinase plasminogen activator system , 2006, British Journal of Cancer.

[38]  D. Noonan,et al.  Tumor inflammatory angiogenesis and its chemoprevention. , 2005, Cancer research.

[39]  E. Arnoldi,et al.  Increased toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution. , 2005, The American journal of pathology.

[40]  L. Rosen.  VEGF-targeted therapy: therapeutic potential and recent advances. , 2005, The oncologist.

[41]  C. Garlanda,et al.  Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[42]  K. Kuenzler,et al.  Hepatocyte growth factor treatment ameliorates diarrhea and bowel inflammation in a rat model of inflammatory bowel disease. , 2004, Journal of pediatric surgery.

[43]  S. Akira,et al.  Toll-like receptors: critical proteins linking innate and acquired immunity , 2001, Nature Immunology.

[44]  A. Medvedev,et al.  Bacterial Lipopolysaccharide and IFN-γ Induce Toll-Like Receptor 2 and Toll-Like Receptor 4 Expression in Human Endothelial Cells: Role of NF-κB Activation1 , 2001, The Journal of Immunology.

[45]  A. Aderem,et al.  Toll-like receptors in the induction of the innate immune response , 2000, Nature.

[46]  K Raja,et al.  Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. , 2000, Cancer research.

[47]  L. Baldini,et al.  Soluble Cytokine Levels Correlate with the Activity and Clinical Stage of Hodgkin's Disease at Diagnosis , 2000, Leukemia & lymphoma.

[48]  S. Devesa,et al.  Incidence of colorectal carcinoma in the U.S. , 1999, Cancer.

[49]  D. Steinberg,et al.  Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[50]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[51]  S. Rubin,et al.  Interleukin‐6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer , 1994, Cancer.

[52]  J. Blay,et al.  Epidermal growth factor promotes the chemotactic migration of cultured rat intestinal epithelial cells , 1985, Journal of cellular physiology.

[53]  C. Melief,et al.  Cancer immunology. , 2011, Current opinion in immunology.

[54]  E. Jaffee,et al.  Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. , 2010, Cellular immunology.

[55]  I. Fidler,et al.  Vascular Biology, Atherosclerosis and Endothelium Biology Circulating Monocytes Expressing CD31 Implications for Acute and Chronic Angiogenesis , 2022 .

[56]  I. Witz.  Tumor-microenvironment interactions: dangerous liaisons. , 2008, Advances in cancer research.

[57]  P. Allavena,et al.  Linking inflammation reactions to cancer: novel targets for therapeutic strategies. , 2008, Advances in experimental medicine and biology.

[58]  Lisa M. Coussens,et al.  Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression , 2007 .

[59]  L. Coussens,et al.  Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.

[60]  A. Leathem,et al.  Expression of the CD15 antigen (Lewis x) in breast cancer , 2004, The Histochemical Journal.

[61]  A. Medvedev,et al.  Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. , 2001, Journal of immunology.

[62]  D. Novick,et al.  Enhancement of interleukin 6 cytostatic effect on human breast carcinoma cells by soluble IL-6 receptor from urine and reversion by monoclonal antibody. , 1992, Cytokine.